RSS Alerts

Share

More services

Related Links

Related Stories

  • Most downloaded review Q1 2009: Target discovery from data mining approaches
    The most downloaded review article from Drug Discovery Today from the first quarter of 2009 deals with the topic of target discovery from the informatics perspective. It would be difficult to overstate the value to Pharma of identifying and validating the most relevant therapeutic targets. In this article, Yang, Adelstein and Kassis outline text mining, its value and limitations and application to target discovery. In addition, they cover the field of emerging and integrated data mining approaches.
  • New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy
    Cancer Research Technology, Merck Serono, Cancer Research UK, Cardiff University and The Institute of Cancer Research are set to begin a new research collaboration that will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.
  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance.
    Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced that it has entered into a 3-year collaboration with the Fox Chase Cancer Center (Fox Chase). The focus of the collaboration is to apply rAAV gene targeting in mouse embryonic stem (ES) cells, and for the discovery of genes involved in resistance to EGFR-targeted therapies in human cancer, such as PI3K.
  • Senectus Therapeutics and AstraZeneca Collaborate to Identify Triggers to Cell Aging
    Senectus Therapeutics has signed a deal to screen a selection of AstraZeneca’s chemical compound library to identify those which trigger a key element of cancer cell ageing – called senescence. Senescent cells are those which after many rounds of cell growth and division enter a ‘sleep’ phase where the normal cell cycle is stopped. This blocks the uncontrolled growth and division of cells. It is a natural mechanism to prevent cancer. But cancer cells find ways to trick their way past this block and continue to grow and divide. Understanding the triggers to cell ageing may reveal molecular targets for completely new ways to treat cancer.

Top 5 Stories

News

Industry and academia team up in three-way collaboration to identify natural substances that can bind to orphan G-protein-coupled receptors

23 September 2009

Findings could lead to new targets for drug discovery.

DiscoveRx Corporation, GlaxoSmithKline (GSK) and Medical Research Council Technology (MRCT) have announced a three-way alliance to seek out natural substances that bind to G-protein-coupled receptors (GPCRs). Through the identification of the natural ligand for these receptors, it is anticipated that this work will identify and validate new drug targets that could ultimately help develop new therapies; compounds that modulate GPCRs are already the basis of many licensed medicines.

The human genome encodes roughly 350 GPCRs, which respond to substances known as ligands. These ligands include hormones, growth factors and proteins. Activation of the receptor by the ligand triggers signalling systems within the cell. These signalling systems are pivotal to normal cell biology and are involved in disease processes.

Despite intensive efforts, there remain at least 100 orphan GPCRs – receptors that have no known ligand or function. Identifying the ligand and role of these orphan GPCRs could potentially open up new areas of biology for therapeutic intervention and drug discovery.

This new industrial–academic collaboration will use the novel PathHunter™ ß-arrestin assay technology on an unprecedented scale to identify the ligands for some of these orphan GPCRs. This systematic approach will target the 100 ‘Family A’ GPCRs that remain classified as orphan receptors with no known biological ligand. After the identification of ligands, certain receptors will progress into high-throughput compound screens to be performed at either MRCT or GSK to identify lead molecules to support drug discovery.

GSK has had considerable success at pairing orphan GPCRs with ligands and will provide the GPCR ligand banks, laboratory equipment and laboratory space. DiscoveRx will provide access to stable cell lines expressing orphan GPCRs formatted in the PathHunter™ ß-arrestin assay (~90 orphan GPCRs), and MRCT will provide scientific staff to perform project activities and identify academic collaborators to characterize ligand-matched GPCRs.

G-protein-coupled receptors (GPCRs) are a family of proteins that are found widely throughout the body and play a fundamental part in physiology and pathophysiology. As such, they are potential targets for therapeutic intervention in many, if not most, diseases.

 

This article is featured in:
Biotherapeutics  •  Novel Technologies

 

Comment on this article

You must be registered and logged in to leave a comment about this article.

Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water